Insulin-like growth factor-I (IGF-I) and -II are important local regulators of bone metabolism, but their role as determinants of human bone mass is still unclear. In the present study, we analyzed the concentration of IGF-I and -II in the bone matrix of 533 human biopsies from the iliac crest that were obtained during surgery for early breast cancer. There was an inverse association of bone matrix IGF-I concentration with age that was unaffected by menopause. Bone matrix IGF-I was positively associated with histomorphometric and biochemical parameters of bone formation and bone resorption and with cancellous bone volume. Based on the estimates of the linear regression analysis, women with a bone matrix IGF-I concentration 2 SD above the mean had a 20% higher bone volume than women with a bone matrix IGF-I concentration 2 SD below the mean. In contrast, serum IGF-I was neither correlated with bone turnover nor with bone volume and was only weakly associated with bone matrix IGF-I when adjusted for the serum concentration of IGF binding protein-3. Bone matrix IGF-II was positively associated with the osteoblast surface, but in contrast to IGF-I, tended to be positively associated with age and was unrelated to cancellous bone volume.
volume and was only weakly associated with bone matrix IGF-I when adjusted for the serum concentration of IGF binding protein-3. Bone matrix IGF-II was positively associated with the osteoblast surface, but in contrast to IGF-I, tended to be positively associated with age and was unrelated to cancellous bone volume.
In summary, our study suggests the following. 1) The concentration of IGF-I in cancellous bone undergoes age-related decreases that are similar to those of circulating IGF-I. 2) Menopause has no effect on this age-related decline. 3) Physiological differences in bone matrix IGF-I are associated with differences in iliac crest cancellous bone volume. 4) Bone matrix IGF-I is a better predictor of cancellous bone volume than circulating IGF-I. 5) The role of IGF-II in human bone tissue is clearly distinct from that of IGF-I. (J Clin Endocrinol Metab 83: 2331-2337, 1998) I NSULIN-like growth factor-I (IGF-I) and -II are stored in large amounts in human bone matrix (1) . Both IGF species are capable of stimulating bone formation and bone resorption in vitro and in laboratory animals and humans in vivo, and are thought to have an anabolic effect on bone mass (2, 3) . Several previous studies have examined the relationship between circulating IGFs and human bone metabolism (4 -17) . However, given the complexity of the IGF system, measurement of serum IGF-I or -II levels may or may not provide meaningful information on the actual levels of these growth factors available in bone tissue. Only few studies have directly examined the concentration of IGF-I and -II in human bone tissue (18 -22) . In the present study, we examined the concentration of IGF-I and -II in a large sample of iliac crest bone biopsies from pre-and postmenopausal women and looked at the relationship of bone matrix IGF-I and -II with age, menopause, bone turnover, bone volume, and circulating IGF components.
Materials and Methods

Bone samples
Between 1991 and 1996, 533 Jamshidi bone biopsies from the anteriorsuperior iliac crest were obtained during surgery for breast cancer at the Gynecology Department of the University of Heidelberg. Cortical bone was separated from cancellous bone with a scalpel blade under a dissection microscope. The biopsies were part of a prospective study that examines the impact of local bone growth factors on the future development of bone metastases. For the present study we only analyzed bone samples from women who had an early tumor stage (T1, T2), no metastases at the time of surgery, normal serum calcium concentrations, serum concentrations of PTH-related peptide below the detection limit of 5 pmol/L by RIA (23) , and no other evidence of systemic tumor disease. Of the 533 women, 192 women were premenopausal [mean age, 42.8 Ϯ 6.4 (sd) yr; range, 25-57 yr], 235 were postmenopausal and did not receive hormonal replacement therapy (mean age, 61.9 Ϯ 8.4 yr; range, 37-83 yr), and 76 had received hormonal replacement therapy before surgery (mean age, 55.8 Ϯ 5.9 yr; range, 39 -72 yr). In the remaining 30 women, menopausal status could not be reliably determined. Blood samples were obtained in a subset of 164 women after overnight fasting before surgery for the measurement of osteocalcin, bone-specific alkaline phosphatase (BAP), and circulating IGF components. The study was reviewed and approved by the institutional review board. Bone and serum samples were stored at Ϫ80 C until further analysis.
Bone matrix extraction
The skeletal concentrations of IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) were determined in extracts from a single bone biopsy from the left iliac crest. The biopsies were immersed in liquid nitrogen and mechanically crushed into small fragments of several millimeters in diameter. The fragments were repeatedly washed in cold distilled water until the washings were free of blood and defatted in cold isopropylether. The defatted bone fragments were then ground into smaller particles (40 -60 m) in a liquid nitrogen-cooled freezer mill (Raetsch, Haan, Germany). The yield of mineralized bone powder varied between 20 mg and 50 mg, depending on biopsy size.
Duplicate extractions of the IGFs were performed from 15 mg of lyophilized bone powder each, as described previously (24) , with the exception that the bone extracts were redialyzed against 10 mm acetic acid instead of PBS. In 34% and 7% of the samples, less than 15 mg of bone powder were available for one or both extractions, respectively. The minimum amount of bone powder for a single extraction was 6 mg. The lyophylized bone powder was placed in microcentrifuge tubes (Twist-lock, Eppendorf, Hamburg, Germany), and 1.7 mL extraction solution (see below) was added. Spectrapor 3 dialysis tubing (3.5-kDa cutoff; Spectrum Medical Industries, Houston, TX) was then placed over the tube opening and secured by a melted out tube cap, as described by Overall et al. (25) . The tubes were then inverted and firmly fixed upside down in a circular rack floating on top of the extraction solution (600 mL for 30 tubes). Extraction was achieved by dialysis against 0.05 m tetrasodium EDTA (Serva, Heidelberg, Germany), 4 m guanidin-HCL (Sigma, Deisenhofen, Germany), 30 mm Tris (Merck, Darmstadt, Germany), and 1 mg/mL BSA (Sigma; RIA grade) at a pH of 7.4. The following protease inhibitors were added to the extraction solution: 5 mm benzamidine-HCl, 1 mm phenylmethylsulfonyl fluorid, and 0.1 m ⑀-aminocaproic acid (Sigma). Dialysis was carried out at 4 C under constant stirring for 24 h. After extraction, the samples were redialyzed against 10 mm acetic acid (pH 7.4) for 72 h. Dialysis medium (600 mL for 30 tubes) was replaced every 24 h. The supernatant extracts were recovered after centrifugation at 5000 ϫ g for 10 min and stored at Ϫ80 C until assayed for growth factor activity.
The recovery of the IGF components was determined by spiking bone powder from the human iliac crest with known amounts of purified IGF-I, -II, or IGFBP-3 before extraction. The mean recovery of IGF-I, -II, and IGFBP-3 was 98%, 92%, and 95%, respectively. Coefficients of variance of the extraction and measurement procedure were determined by extracting three different pools of human bone matrix containing low, medium, and high concentrations of the three IGF components over a period of time and assaying the concentration of these growth factors individually by duplicated measurements for IGF-I, -II, and IGFBP-3. The combined interassay variance for repeated extractions was less than 15% for all three IGF components. Preceding experiments had shown that the yield of extractable growth factors from human bone could not be improved by reextraction. Furthermore, no additional growth factors were released when the residual bone matrix was digested with highly purified collagenase, suggesting a complete recovery of the endogenous growth factors.
Measurement of serum and bone matrix IGF components
IGF-I in the bone matrix extracts and in serum was measured using a polyclonal rabbit antibody against human IGF-I (Mediagnost, Tü -bingen, Germany) and recombinant human IGF-I (GroPep, Adelaide, Australia) as a tracer and standard (11, 24) . IGFBP artifacts were avoided by initial dissociation of IGF from the binding proteins present using an acidic buffer. Reassociation was then blocked by inducing binding protein saturation through the addition of excess IGF-II (Mediagnost) (26) . This assay method has been extensively validated and shows good correlations with measurements obtained by acidic size-exclusion chromatography (27) . Moreover, previous experiments had shown that with this procedure unlabeled IGF-I is completely recovered after preincubation with the extracts, and that there is no change in the measurement of endogenous IGF-I in the presence of up to 10 ng/mL IGFBP-3 (24). IGF-II cross-reactivity in this RIA was Ͻ 0.05%. Interassay variation was 6%. IGF-II was measured by RIA using a polyclonal rabbit antibody against human IGF-II (Mediagnost). Measurements were calibrated against recombinant human IGF-II (GroPep). Assay conditions were similar to those described for the IGF-I RIA, except that excess IGF-I was used to block interferences caused by IGFBPs. Validation was performed as described for IGF-I. In particular, there was no change in the measurement of endogenous IGF-II in the presence of up to 10 ng/mL IGFBP-3. Cross-reactivity of the IGF-II antibody with IGF-I was less than 0.05%. Interassay coefficient of variation was 6.5%. IGFBP-3 was measured using a commercial enzyme-linked immunosorbent assay (ELISA) from Diagnostic Systems Lab. (Webster, TX). Interassay coefficient was 7%. Cross-reactivity with IGF-I, -II, and IGFBP-1 was less than 0.05%. Extracts from two independent extractions of bone powder from the same iliac crest biopsy were assayed in duplicate for all three IGF components.
The residual matrix after extraction was resuspended twice in distilled water, lyophilized, and weighted. The concentration of the IGFs in the bone matrix was expressed per milligram mineralized bone or per milligram dry weight of the residual bone matrix, as described previously (24) . The normalized values of the two separate extractions were then averaged. Both normalized indices were highly correlated (r Ͼ 0.9 for all IGF components).
Bone histomorphometry
Histomorphometric measurements at the iliac crest were independently performed in two Jamshidi biopsies from the left and right iliac crest. The biopsies were 2 mm in diameter and had an average length of 3-4 cm. The means of the histomorphometric indices from the left and right iliac crest were averaged. All bone samples that had been assigned to histomorphometry were fixed in 70% ethanol and embedded undecalcified in methyl methacrylate. Three-micrometer sections were cut with a Jung Supercut microtome (Cambridge Instruments, Nussloch, Germany), and stained according to a modified Goldner method. Cancellous bone volume [cancellous bone volume in percent of tissue volume (BV/TV%)] was determined by image analysis (Digithurst, Nü rnberg, Germany) at a 25-fold magnification. The coefficient of variance for BV/TV% between the left and the right iliac crest was 14.6%. The percentages of the cancellous bone surface covered with osteoblasts (OB.S/BS) and undergoing active bone resorption (OC.S/BS) were evaluated with a Merz grid at a 100-fold magnification. All measurements were blindly performed without knowledge of the corresponding IGF concentrations.
Measurement of serum osteocalcin and BAP
Osteocalcin was measured by chemoluminescence (BRAHMS, Berlin, Germany) using an antibody directed against the N-terminal region of the osteocalcin molecule. The assay had an intraassay precision of 4.7% and an interassay precision of 7.5%, respectively. BAP was determined by ELISA (Metra, Mountain View, CA). Intra-and interassay coefficients of variance were 3.9% and 7.6%, respectively. All samples were measured in duplicates and the means calculated.
Statistical analysis
Differences between groups were analyzed by one-way ANOVA using Fisher's test for multiple comparisons. Simple and partial Pearson's correlations were used to describe the associations between two continuous variables. All analyses were performed with the Statistical Analysis System software program (SAS Institute, Cary, NC).
Results
Associations of bone matrix IGF-I and -II and IGFBP-3 with age
The concentration of IGF-I in iliac crest bone was inversely related to age. IGF-I concentrations in the eighth decade were 35% lower than in the third decade ( Fig. 1A and Table 1 ). Age-related differences in IGF-I of a similar magnitude were observed in serum (r ϭ Ϫ0.18, P ϭ 0.02, n ϭ 164; r ϭ Ϫ0.30 P Ͻ 0.0001 when three outliers were excluded). The slope of the inverse association between bone matrix IGF-I and age was most pronounced in premenopausal women, but a weak inverse association between bone matrix IGF-I and age was still present in postmenopausal women (Fig. 1A) . This difference in the slope of the regression of IGF-I on age was also present when the women were arbitrarily stratified into women less than 50 yr of age (r ϭ Ϫ0.21, P ϭ 0.003, n ϭ 200) and more than 50 yr of age (r ϭ Ϫ0.13, P ϭ 0.02, n ϭ 333). There were no significant differences in bone matrix IGF-I concentrations between age-matched 45-to 55-yr-old premenopausal women, postmenopausal women, and postmenopausal women on hormonal replacement therapy (HRT) ( Table 2 ), suggesting that the age-related decline in bone matrix IGF-I is independent from menopause.
The bone matrix concentration of IGF-II was 8-fold higher than that of IGF-I ( Table 1) . As opposed to IGF-I, serum IGF-II concentrations failed to be associated with age (r ϭ ϩ0.04, P ϭ 0.64). Bone matrix IGF-II concentrations were even slightly positively correlated with age (Fig. 1B) . Menopause had no effect on bone matrix IGF-II concentrations ( Table 2) .
The concentration of bone matrix IGFBP-3 was weakly inversely related to age in premenopausal women (r ϭ Ϫ0.16; P ϭ 0.03), but failed to be associated with age in postmenopausal women with HRT (r ϭ Ϫ0.05, P ϭ 0.65) and without HRT (r ϭ ϩ0.05, P ϭ 0.41).
Association between bone matrix IGFs and bone turnover
Bone matrix IGF-I was positively associated with the percentage of the osteoblast-covered cancellous bone surface, the percentage of the bone surface undergoing active bone resorption, and with serum osteocalcin levels ( Table 3) . With the exception of the osteoclast surface, these associations were independently observed both for pre-and postmenopausal women (data not shown). Interestingly, bone matrix IGF-I failed to be associated with serum BAP, despite the fact that BAP was significantly correlated with serum osteocalcin (n ϭ 166, r ϭ ϩ0.54, P Ͻ 0.0001) and with the osteoblastcovered surface (n ϭ 96, r ϭ ϩ0.28, P ϭ 0.006). In contrast, the strength of the relationship of intact serum PTH (r ϭ ϩ0.34, P Ͻ 0.0001) and free serum T 3 (fT 3 ) (r ϭ ϩ0.20, P ϭ 0.001) with BAP in the same sample collective even exceeded that of the relationship of PTH (r ϭ ϩ0.25, P Ͻ 0.0001) and fT 3 (r ϭ ϩ0.12, P ϭ 0.06) with osteocalcin (n ϭ 246 including samples for which no bone matrix IGF-I measurements were available).
Bone matrix IGF-II was positively associated with the percentage of the osteoblast-covered cancellous bone surface but not with the percentage of the bone surface undergoing active bone resorption, serum osteocalcin, or serum BAP (Table 3) .
Association between bone matrix IGFs and cancellous bone volume at iliac crest
Cancellous bone volume at the iliac crest was inversely related to age (n ϭ 466, r ϭ Ϫ0.15, P ϭ 0.001). The concentration of bone matrix IGF-I was positively associated with the cancellous bone volume (Fig. 2 and Table 4 ). This association was independently observed both for pre-and postmenopausal women. Adjustment for age had no substantial effect on the strength of the association (Table 4) . On the other hand, adjustment for IGF-I partially explained the age-associated bone loss (r ϭ Ϫ0.11, P ϭ 0.02 after adjustment for IGF-I). Based on the estimates of the linear regression equation, women with an IGF-I concentration 2 sd above the mean (0.6 ng/mg) had a 20% higher average cancellous bone volume than women with an IGF-I concentration 2 sd below the mean (0.13 ng/mg).
No association was observed between the bone matrix concentration of IGF-II and cancellous bone volume. There even was a spurious negative association between bone matrix IGF-II and bone volume in postmenopausal women (Table 4) .
Association between bone matrix IGF-I and serum IGF-I
The relationship between the concentrations of IGF-I in the bone matrix and in the circulation was examined in a subset Premenopausal women (E) (r ϭ ϩ0.10, P ϭ 0.18, n ϭ 192). Postmenopausal women without HRT (F) (r ϭ ϩ0.001, P ϭ 0.98, n ϭ 235). Postmenopausal women on HRT (Ⅺ) (r ϭ ϩ0.14, P ϭ 0.23, n ϭ 76). There was a weak positive association of bone matrix IGF-II with age when data from all 533 women were combined (r ϭ ϩ0.12, P ϭ 0.007).
of 164 women for whom both serum and bone matrix IGF measurements were available. In both compartments, IGF-I concentrations were strongly correlated with the respective concentration of IGFBP-3 in bone matrix or serum (Table 5 ). There was no significant association between the serum levels of IGF-I and the concentration of IGF-I in bone matrix (Table 5 ). However, a weak positive relationship between the two variables became apparent after adjustment of the serum IGF-I concentration for the concentration of serum IGFBP-3. Similar to our findings in the entire sample collective, bone matrix IGF-I in this subset of women was significantly associated with the percentage of the osteoblast-covered bone surface, serum osteocalcin levels, and cancellous bone volume. In contrast, neither serum IGF-I (Table 5 ) nor serum IGF-II and IGFBP-3 were correlated with any parameter of bone turnover or with bone volume, regardless whether serum IGF-I or IGF-II were adjusted for circulating IGFBP-3 or not (data not shown).
Discussion
The present study addresses several questions with respect to the concentration of IGF-I and -II in human bone tissue: Based on the quantitative determination of IGF-I in the bone matrix of a large number of iliac crest bone biopsies, our study confirms that there is an inverse relationship between the IGF-I concentration in human bone matrix and age, similar to the one described in previous studies (19, 21, 22) and similar to the decline of IGF-I in serum with age. Our data suggest that the age-related decline in bone matrix IGF-I is not affected by menopause. Our study further suggests that circulating IGF components are only poorly associated with the IGF-I concentration in the bone matrix. We also show that physiological variations in bone matrix IGF-I are associated with differences in bone turnover and cancellous bone volume. Finally, our study shows that these findings are restricted to IGF-I, because the bone matrix concentration of IGF-II tended to be positively associated with age, and failed to account for any variability in human bone volume.
There are some limitations to our study because of the fact that the biopsies were obtained from women with breast cancer and therefore may not be entirely representative for Pearson's correlation coefficients for simple correlation. All parameters with the exception of osteocalcin were log normalized for analysis. Significant associations:
a P Ͻ 0.05; b P Ͻ 0.01; c P Ͻ 0.001.
the normal female population. Although our selection criteria made it unlikely that the tumor itself had any influence on bone metabolism at the time of surgery; breast cancer has been shown to be associated with a higher bone mass, presumably because of the linked association with higher estrogen exposure (28, 29) . However, because this association is weak, and our sample contained a sufficiently large number of women with both low and high bone volume, this bias is unlikely to invalidate our results. Moreover, because 12% of all women will have breast cancer diagnosed in their lifetime (30) , this is a rather common risk factor. In accordance with previously reported findings at different skeletal sites (19, 21, 22) , we observed an inverse relationship between bone matrix IGF-I at the iliac crest and donor age. This decline in bone matrix IGF-I with age may be related to the decline in the general activity of the GH/IGF axis, but direct age-related decreases in IGF-I production by bone cells may also be involved (31) . Interestingly, the slope of the association between bone matrix IGF-I and age was most pronounced in premenopause, suggesting that the loss of skeletal IGF-I to a large part already occurs during the first half of life. Nevertheless, it should be pointed out that based on the estimates of the linear regression analysis, age explained only 4.4% of the total variability of bone matrix IGF-I, indicating that at least for this particular sample collective, age was only a modest contributor to the overall variability in skeletal IGF-I concentration.
The interaction between estrogens and the GH/IGF-axis is complex. Estrogens augment the pituitary secretion of GH but induce a relative resistance to the stimulatory effect of GH on IGF-I production (32) . The net effect of estrogens on serum IGF-I concentrations, however, depends on the route of administration. Whereas oral estrogens decrease systemic IGF-I levels, presumably via a direct hepatic effect, transdermal delivery of estrogens has no significant effect on circulating IGF-I levels. With respect to bone, estrogens have been shown to augment IGF-I production in rodent osteoblast cell cultures (33, 34) . In contrast, ovariectomy has no effect on (35, 36) or actually increases bone IGF-I (37, 38) in the rat. In the present study, we failed to observe any significant difference in the bone matrix concentration of IGF-I between age-matched 45-to 55-yr-old early postmenopausal women without estrogen replacement, as compared to postmenopausal women on HRT and premenopausal women. Our study therefore suggests that the decline in bone matrix IGF-I with age in women is independent of human menopause, and that physiological concentrations of estrogens have no major impact on the skeletal concentration of bone matrix IGF-I.
The concentration of IGF-I in the bone matrix was significantly positively associated with histomorphometrical parameters of bone formation and bone resorption. Interestingly, the matrix IGF-I concentration was also positively related to circulating osteocalcin levels, but not to serum BAP. We can only speculate on the reason for these differential relationships. Osteocalcin measurements may provide a better reflection of the bone forming surface than BAP measurements, as suggested by a stronger association of the 
Ϫ0.12
Pearson's correlation coefficients for simple correlation and partial correlation after adjustment for age. Data are derived from 164 women for whom both serum and matrix IGF-I measurements were available. Measurements of BV/TV (n ϭ 145) and OB.S/BS (n ϭ 94) were not available for all women. Significant associations:
a P Ͻ 0.05; b P Ͻ 0.01; c P Ͻ 0.001; d P Ͻ 0.0001. * r ϭ Ϫ0.30, P Ͻ 0.0001 when three outliers are excluded. OB.S/BS values were log normalized for analysis.
osteoblast-covered bone surface with serum osteocalcin (r ϭ 0.57, P Ͻ 0.001) than with serum BAP (r ϭ 0.28, P ϭ 0.006). However, in the same sample collective, the strength of the association of intact serum PTH and fT 3 with BAP even exceeded that of the association between these two hormones and serum osteocalcin. IGF-I is known to promote osteoblast differentiation (39) and osteocalcin is a marker for a more advanced osteoblastic phenotype than BAP. It is therefore also possible that the better association of bone matrix IGF-I with serum osteocalcin is in part related to this differentiation-promoting action of IGF-I.
The concentration of bone matrix IGF-I was positively associated with iliac crest cancellous bone volume. Our study suggests that physiological variations in the local IGF-I concentration in human bone tissue may only explain a small percentage of the overall variability of normal bone mass. Nevertheless, based on the estimates of a linear regression analysis, a woman with an IGF-I concentration at the upper limit of the normal distribution (ϩ2 sd) will have a 20% higher cancellous bone volume than a woman at the lower limit (Ϫ2 sd), indicating that local IGF-I concentrations outside of the normal range may be associated with clinically relevant differences in bone mass.
The bone matrix concentration of IGF-II was 8-fold higher than that of IGF-I. However, despite similar anabolic effects of the two IGF species on bone cells in vitro (40) , only IGF-I was associated with bone volume in the present study. Together with the finding that there is no age-related decline in bone matrix IGF-II, this points to a very different role of this IGF species in human bone tissue as compared with that of IGF-I. Recent experiments in primary cultures of rat osteoblasts suggest that IGF-II may be involved in the early strainrelated response of osteoblasts in loading-related modeling (41) .
The concentration of IGF-I and -II in human bone matrix is potentially determined by a number of different variables. These include the circulating concentration of IGF-I and -II, the local production of IGF-I and IGF-II by cells within the bone tissue, and the local production of IGFBPs and binding protein proteases. Evidence for the involvement of the IGFBPs as determinants of the skeletal IGF concentration is provided by the finding that the concentration of IGFBP-3 in the bone matrix explained 19% of the bone matrix IGF-I concentration. In a recent study by Nicolas et al. (20) , the skeletal concentration of IGFBP-5, another IGFBP that is abundant in bone matrix and binds to hydroxyapatite, even explained 39% of the variability of IGF-I in human cortical bone matrix. Unfortunately, sensitive assays for IGFBP-5 or other IGFBPs apart from IGFBP-3 were not available to us in the present study.
Circulating IGF-I was only weakly positively associated with bone matrix IGF-I, and this association became only apparent after adjustment of serum IGF-I for the concentration of its major binding protein in circulation, IGFBP-3. Thus, the amount of IGF-I in bone tissue that is provided by circulating IGF-I may depend on the ratio of IGF-I to IGFBP-3 rather than on the total concentration of serum IGF-I. Indeed, only free IGF-I is thought to be able to cross the capillary endothelial barrier (42) . However, even the ratio of IGF-I to IGFBP-3 explained only 6% of the variability of bone matrix IGF-I, suggesting that circulating IGF-I levels are only a poor predictor of skeletal IGF-I concentrations at the iliac crest.
The lack of correlation between circulating IGF components and trabecular bone volume in the present study is in apparent contradiction to findings from several previous studies reporting significant positive associations between circulating IGF components and bone mass or bone turnover. Reed et al. (10) showed positive associations between circulating IGF-I and several histomorphometric parameters of bone formation in patients with idiopathic osteoporosis. Although these findings were observed in a small number of patients, it is possible that in particular subsets of patients with bone diseases, circulating IGF-I levels may explain variability in bone turnover to a larger extent than in individuals without known bone disease.
Sugimoto et al. (16) recently reported striking associations between circulating IGF-I levels and bone mineral density (BMD) measurements at all skeletal sites in postmenopausal women. However, in a separate study from the same group, only weak associations were observed between serum IGF-I and forearm BMD in perimenopausal women (17) . In the few studies that have examined the relationship between circulating IGF components and parameters of bone metabolism in population-based settings, only weak associations were observed that could be further attenuated by adjustment for age and/or other confounding variables (11) (12) (13) . These weak positive associations may have been missed in the present study because of the larger variability of the histomorphometric measurement as compared with BMD measurements.
We should mention that the changes in circulating IGF-I levels with age were rather modest. In particular, IGF-I serum levels in the younger women were somewhat lower that those reported in previous studies (43) (44) (45) (46) . The reason for this is unclear. There was no obvious difference in fasting or physical condition compared with the older women. The association with age became considerably stronger when three IGF-I-outliers were excluded from analysis. Nevertheless, this did not result in any improvement of the associations between circulating IGF-I levels and bone turnover or volume. Our study therefore clearly suggests that, at least for trabecular bone and the iliac crest, the bone matrix IGF-I concentration is a better predictor of local bone turnover and mass than circulating IGF. Whether this may also apply to cortical bone or different skeletal sites remains to be determined.
